Vepdegestrant shows significant progression-free survival benefits over fulvestrant in advanced breast cancer, highlighting ...

Tel Aviv University researchers say neutrophils can be late-stage breast cancer target and biomarker; Beilinson Hospital ...

The Phase III DESTINY-Breast09 clinical trial has delivered groundbreaking results, demonstrating that ENHERTU® ...

The following is a summary of "Advances and challenges in targeted therapies for HER2-amplified colorectal cancer," published ...

A new FDA application for vepdegestrant offers hope for advanced breast cancer patients with ESR1 mutations, showcasing ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Results from the Phase III VERITAC-2 trial demonstrated that vepdegestrant reduced the risk of disease progression or death ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

US-based Iambic Therapeutics has concluded the dose escalation phase in its multi-centre Phase I/Ib trial of a ...

LONDON, GREATER LONDON, UNITED KINGDOM, June 5, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, the oral proteolysis-targeting chimera ER degrader, vepdegestrant, ...

The Australian company is betting the radionuclide could be an option for patients with HER2-expressing solid tumors who can't tolerate other treatments.